Dianthus Therapeutics (Dianthus Therapeutics) Days Payable : 0.00 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Days Payable?

Dianthus Therapeutics's average Accounts Payable for the three months ended in Mar. 2024 was $2.61 Mil. Dianthus Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil.

The historical rank and industry rank for Dianthus Therapeutics's Days Payable or its related term are showing as below:

DNTH's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.28
* Ranked among companies with meaningful Days Payable only.

Dianthus Therapeutics's Days Payable stayed the same from Dec. 2022 (0.00) to Mar. 2024 (0.00). stayed the same

Dianthus Therapeutics Days Payable Historical Data

The historical data trend for Dianthus Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Days Payable Chart

Dianthus Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Days Payable

Dianthus Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Days Payable	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Dianthus Therapeutics's Days Payable

For the Biotechnology subindustry, Dianthus Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dianthus Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Dianthus Therapeutics's Days Payable falls into.

Dianthus Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Dianthus Therapeutics's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (1.167	+	2.61)	/	2 )	/	0	*	365
=	1.8885					/	0	*	365
=	N/A

Dianthus Therapeutics's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

	Days Payable (Q: Mar. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (2.61	+	2.612)	/	2 )	/	0	*	365 / 4
=	2.611					/	0	*	365 / 4
=	N/A

Dianthus Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

87E:Germany

Address

7 Times Square, 43rd Floor, New York, NY, USA, 10036

Website

https://www.dianthustx.com

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines

From GuruFocus

Fairmount Funds Management LLC Acquires New Stake in Dianthus Therapeutics Inc

By GuruFocus Research • 09-29-2023

Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc

By GuruFocus Research • 09-14-2023